Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon beta-1a: potential implications for protein aggregation and immunogenicity by Torosantucci, Riccardo et al.
Identification of oxidation sites and covalent cross-links in metal
catalyzed oxidized interferon beta-1a: potential implications for
protein aggregation and immunogenicity
Riccardo Torosantucci1,2, Victor S. Sharov2, Miranda van Beers3, Vera Brinks4, Christian
Schöneich2, and Wim Jiskoot1,*
1Division of Drug Delivery Technology, Leiden/Amsterdam Center for Drug Research, Leiden
University, 2300 RA Leiden, the Netherlands 2Department of Pharmaceutical Chemistry,
University of Kansas, Lawrence, KS, USA 3Bioprocessing Technology Institute, Agency for
Science Technology and Research (A*STAR), Singapore 4Department of Pharmaceutics, Utrecht
Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584 CA Utrecht, the
Netherlands
Abstract
Oxidation via Cu2+/ascorbate of recombinant human interferon beta-1a (IFNβ1a) leads to highly
immunogenic aggregates, however it is unknown which amino acids are modified and how
covalent aggregates are formed. In the present work we mapped oxidized and cross-linked amino
acid residues in aggregated IFNβ1a, formed via Cu2+/ascorbate catalyzed oxidation. Size
exclusion chromatography (SEC) was used to confirm extensive aggregation of oxidized IFNβ1a.
Circular dichroism and intrinsic fluorescence spectroscopy indicated substantial loss of secondary
and tertiary structure, respectively. Derivatization with 4-(aminomethyl) benzenesulfonic acid was
used to demonstrate, by fluorescence in combination with SEC, the presence of tyrosine (Tyr)
oxidation products. High performance liquid chromatography coupled to electrospray ionization
mass spectrometry of reduced, alkylated and digested protein was employed to localize chemical
degradation products. Oxidation products of methionine, histidine, phenylalanine (Phe),
tryptophan and Tyr residues were identified throughout the primary sequence. Covalent crosslinks
via 1,4- or 1,6-type addition between primary amines and DOCH (2-amino-3-(3,4-
dioxocyclohexa-1,5-dien-1-yl) propanoic acid, an oxidation product of Phe and Tyr) were
detected. There was no evidence of disulfide bridge, Schiff base, or dityrosine formation. The
chemical cross-links identified in this work are most likely responsible for the formation of
covalent aggregates of IFNβ1a induced by oxidation, which have previously been shown to be
highly immunogenic.
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Recombinant human interferon beta (IFNβ), a cytokine with anti-inflammatory and tumor-
suppressor functions(1) is considered as the first choice treatment of multiple sclerosis, a
severe neurodegenerative autoimmune disease(2). Interferon beta-1a (IFNβ1a), in contrast to
interferon beta-1b (IFNβ1b)(3), is glycosylated at asparagine 80(4) carrying mainly
biantennary and triantennary glycan structures(5, 6). IFNβ1a has an average molecular
weight of about 22.5 kDa, contains 166 amino acid residues and is produced in Chinese
hamster ovarian (CHO) cells(6). As described by Karpusas et al.(7), the protein contains five
alpha helices, an intramolecular disulfide bridge between cysteines in positions 31 and 141,
and a free cysteine (Cys) in position 17. Like many other protein therapeutics, IFNβ is prone
to aggregation, which has been correlated with enhanced immunogenicity(8). Furthermore, it
has been demonstrated that the removal of protein aggregates reduces the immunogenicity
of IFNβ formulations(9–11). In addition, IFNβ1b (Betaferon), which contains more
aggregates than IFNβ1a products (Avonex, Rebif), has been found to be the most
immunogenic IFNβ product in several preclinical and clinical studies(12, 13).
Protein aggregates induced by metal-catalyzed oxidation (MCO) have been found to be
particularly immunogenic in preclinical models. For instance, Hermeling et al. showed that
recombinant human interferon alpha-2b (IFNα2b) forms immunogenic aggregates upon
oxidative stress induced by Cu2+/ascorbate catalyzed oxidation, using a transgenic mouse
model immune tolerant to the human protein(14, 15). Similarly, IFNβ1a aggregates and
monoclonal antibody aggregates, both produced via the same oxidative system, were shown
to be highly immunogenic in transgenic immune tolerant mouse models(8, 16). We therefore
believe that characterization of chemical modifications and cross-links caused by Cu2+/
ascorbate catalyzed oxidation is of high importance, since these data may shed light on
structure-immunogenicity relationships for IFNβ1a and potentially other therapeutic
proteins.
The scope of the present work was to identify the chemical modifications in Cu2+/ascorbate
oxidized IFNβ1a, including covalent cross-links that may be involved in aggregation. Here
we report a comprehensive characterization of oxidative modifications in IFNβ1a following
MCO and discuss putative mechanisms of MCO-induced IFNβ1a aggregation. Our data
strongly support the formation of electrophilic oxidation products, which can be further
involved in aggregate formation via 1,4- or 1,6-type addition to pre-existing protein
nucleophiles, such as primary amine groups, in agreement with our recent mechanistic
studies on insulin as a model protein(17).
Materials and Methods
Materials
IFNβ1a (0.26 mg/ml protein in 20 mM sodium acetate buffer, pH 4.8, containing 154 mM
arginine) was kindly provided by Biogen Idec Inc. (Cambridge, MA, USA). PNGase F, L-
ascorbic acid, ethylenediamine tetraacetic acid (EDTA), copper dichloride, arginine,
monobasic and dibasic sodium hydrogen phosphate, ammonium bicarbonate (ABI), sodium
chloride, sodium azide, SDS, dithiothreitol (DTT), iodoacetamide, glacial acetic acid, and
acetonitrile were purchased from Sigma-Aldrich (St. Louis, MO, USA). MilliQ water was
used for the preparation of all the formulations. All chemicals were of analytical grade and
used without further purification. 4-(aminomethyl) benzenesulfonic acid (ABS) was
synthesized according to a published procedure(18). Endoproteinases Glu-C and trypsin were
purchased from Promega (Madison, WI, USA).
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Preparation of untreated and oxidized IFNβ1a formulations
IFNβ1a was prepared and treated as reported by van Beers et al.(8). Briefly, the protein
solution was dialyzed against 100 mM sodium phosphate buffer and 200 mM sodium
chloride, pH 7.2 (PBS). This dialyzed solution is referred to as untreated IFNβ1a. To obtain
oxidized IFNβ1a, untreated IFNβ1a, diluted to 200 µg/ml with PBS, was incubated with 4
mM ascorbic acid and 40 μM CuCl2 for 3 hours at room temperature. The oxidation reaction
was stopped by adding 100 mM EDTA to a final concentration of 1 mM as previously
reported(17).
ABS derivatization
Untreated and oxidized protein (0.2 mg/mL) were dialyzed against 50 mM ABI, pH 8.0,
using a 3.5-kDa MWCO Slide-A-Lyzer Cassette (Asheville, NC, USA), before
derivatization with ABS. To 250 μL of dialyzed samples 7.5 μL of 0.1 M sodium hydroxide
were added to adjust the pH to 9.5. Then 100 mM ABS stock solution was added to a final
concentration of 10 mM. Subsequently, 5 mM K3Fe(CN)6 stock solution in milliQ water
was added to a final concentration of 0.5 mM. The reaction was conducted for 1 hour at
room temperature, before performing SEC analysis or fluorescence measurement (as
reported below in the section Size exclusion chromatography and Fluorescence
spectroscopy, respectively). Controls for non-specific fluorescence included (i) oxidized and
non-oxidized protein prior to derivatization and (ii) reagents alone (i.e. ABS/K3Fe(CN)6)
incubated under the same conditions.
Size exclusion chromatography
To determine the aggregate content and to investigate the effect of reducing agents on
oxidized and untreated IFNβ1a, SEC was performed by using a TSKgel Super SW2000
column protected by a Super SW guard column (Sigma Aldrich, St. Louis, MO, USA). An
SPD-6AV UV and fluorescence detector (Shimadzu, Columbia, MD, USA) was used to
record the chromatograms at a wavelength of 280 nm and at excitation/emission wavelength
combination of 295/350nm, respectively. A flow rate of 0.35 ml/min was applied using a
515 HPLC pump and 717 Plus autosampler (Waters, Milford, MA, USA). The mobile phase
consisted of 200 mM sodium chloride, 0.05% (w/v) sodium azide and 0.1% (w/v) SDS in
100 mM sodium phosphate, pH 7.2, which was filtered through a 0.2-μm filter prior to use.
To detect fluorescent benzoxazole products in the ABS-derivatized samples, we used an
Insulin HMWP Column, 7.8 × 300 mm (Waters) connected to a HPLC system (Shimadzu,
Columbia, MD, USA) coupled with a Shimadzu RF-20A fluorescence detector. Excitation
and emission wavelengths were set at 360 and 490 nm, respectively. The mobile phase
composition and flow rate were as previously reported(19).
Fluorescence spectroscopy
The emission spectra of the ABS-derivatized samples, diluted twofold in ABI, were
measured in a 0.5-mL quartz fluorescence cuvette with an RF-5000U fluorescence
spectrophotometer (Shimadzu) with excitation and emission wavelengths range set at 360
and 400–600 nm, respectively, and bandwidths set at 5 nm.
To test the potential presence of dityrosine, fluorescence of the oxidized IFNβ1a was
measured in triplicate, using excitation and emission wavelengths set at 315 and 420 nm,
respectively, as described previously(20).
Tryptophan (Trp) intrinsic fluorescence was measured with a TECAN infinite M1000
fluorometer (Tecan group Ltd., Männedorf, Switzerland) upon excitation at 295 nm and
emission recorded from 310–500 nm with a step size of 2 nm, 50 flashes (frequency 400
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Hz), a gain of 150 and a Z-position of 20.0 mm. Duplicates of 200 μL of each sample were
analyzed in black polystyrene 96-well plates (Greiner Bio-One, Frickenhausen, Germany).
Circular dichroism spectroscopy
Circular dichroism (CD) spectra of untreated and oxidized IFNβ1a (0.1 mg/mL) were
recorded from 190 to 250 nm, using a Jasco J-815 CD spectrometer (Jasco International,
Tokyo, Japan). Analyses were performed in a 1-mm (far-UV CD) path length quartz cuvette
at 25 °C using a scan rate of 100 nm/min, a response time of 2 s, and a bandwidth of 1 nm.
Each spectrum was the result of an averaging of six repeated scans and background was
corrected with the corresponding buffer spectrum. The CD signals were converted to mean
residue ellipticity [θ]mrw, λ, using a mean residue weight (MRW, calculated as MRW = M/
(N−1), where M is the average molecular weight of the untreated (glycan-free) protein (i.e.
20027 Da, based on the protein’s chemical formula C908H1408N246O252S7) and N is the
number of amino acid residues in the chain).
Reduction, alkylation and digestion
Untreated and oxidized protein (0.2 mg/mL) were dialyzed against 50 mM ABI, pH 8.0,
using a 3.5-kDa MWCO Slide-A-Lyzer Cassette (Asheville, NC, USA), and reduced by
addition of 50 mM DTT, freshly prepared in 50 mM ABI, pH 8.0, to a final concentration of
5 mM. The samples were incubated for 45 minutes at 45 °C using a Thermo NES heating
bath (Thermo Scientific, NC, USA). Subsequently, 200 mM iodoacetamide, freshly prepared
in 50 mM ABI, pH 8.0, was added to a final concentration of 20 mM. The digestion was
performed as follows: IFNβ1a was incubated with Glu-C endoproteinase at a IFNβ1a/Glu-C
ratio of 10:1 (w/w), for 1 hour at 37 °C. Next, trypsin was added (IFNβ1a/trypsin ratio 20:1
(w/w)) and the mixture was incubated for an additional hour at the same temperature.
Finally, 4 μL of a solution of PNGase F, dissolved according to the manufacturer’s protocol,
was added to 76 μL of the protein mixture, which was then incubated overnight at 37 °C.
MS/MS analysis
Digested and non-digested samples were analyzed by means of an LTQ-FT hybrid linear
quadrupole ion trap Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer
(Thermo-Finnigan, Bremen, Germany)(21). The MS/MS spectra were analyzed with the
web-based software MassMatrix(22–25), which was used to simulate mass spectra and the
theoretical fragment tables of the b- and y-ions(26) for the native, oxidized and cross-linked
peptide products. The simulated spectra were compared to the experimental MS/MS spectra
in order to validate the proposed product and cross-link structures. A mass accuracy
sensitive probability-based scoring algorithm for database searching of tandem mass
spectrometry data by MassMatrix software was employed for peptide identification; the
manual filter was set at mass/charge ratio (m/z) accuracy < 0.1 amu for both parent peptide
and fragment ions.
Results
Comparison of untreated and oxidized IFNβ1a by SEC and spectroscopic methods
SEC analysis was used to verify whether the aggregation profile of oxidized IFNβ1a was
similar to that observed earlier(8) and to study a potential involvement of disulfide bridging
in aggregate formation. Comparison of the chromatograms of untreated and oxidized
IFNβ1a (Figure 1A) shows extensive aggregation of the oxidized product and both
chromatograms are in close agreement with the results published by van Beers et al.(8).
Furthermore, the treatment of oxidized IFNβ1a with DDT did not have a major impact on
the elution behavior, indicating that the majority of the aggregates were formed by non-
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reducible covalent bonds. In contrast, we observed that for untreated IFNβ1a, the reduction
with DDT resulted in a decrease in dimer content by approximately 60% (Figure 1A),
indicating that most of the dimers in the untreated IFNβ1a were formed through disulfide
bridging.
SEC with fluorescence detection of ABS-tagged proteins was used to study whether the
monomers or aggregates contain DOPA (3,4-dihydroxyphenylalanine) and/or DOCH (2-
amino-3-(3,4-dioxocyclohexa-1,5-dien-1-yl) propanoic acid), produced by oxidation of
tyrosine (Tyr) and/or phenylalanine (Phe) residues and subject to fluorogenic derivatization
with ABS(17) and/or 5-hydroxytryptophan, a Trp oxidation product which can also form
fluorescent benzoxazole products upon ABS derivatization(27, 28). Our data show that after
derivatization of the oxidized and dialyzed protein with ABS, the total SEC fluorescence
peak area (i.e. the sum of all the peak areas under the curve) for the ABS-derivatized
oxidized IFNβ1a is about six fold higher than that of the ABS-derivatized untreated protein
(Figure 1B), indicating that MCO of IFNβ1a leads to formation of DOPA/DOCH and/or 5-
hydroxytryptophan residues in the oxidized protein. ABS derivatization of non-oxidized
IFNβ1a also produces a weak fluorescent signal mainly associated with protein monomer
(Figure 1B), suggesting a background oxidation in the untreated protein. The ABS
fluorescence of ABS derivatized oxidized and untreated IFNβ1a was also measured by
steady-state fluorescence. The results show a seven fold increase in fluorescence intensity
for the oxidized protein (Figure 2), which is consistent with the SEC data.
Further structural characterization was performed by CD (Figure 3) and intrinsic steady-state
fluorescence measurements (Figure 4). Likely as a result of oxidation and cross-link
formation, it was found that the content of alpha helix in oxidized IFNβ1a had decreased, as
indicated by the dro p in negative CD signal, with a concomitant increase in random coil
structure, as indicated by the higher 208/222 nm ratio measured for the oxidized protein
(1.041 ± 0.024) as compared with its native counterpart (0.729 ± 0.004)(29, 30). Moreover, a
substantial decrease of Trp fluorescence was observed, pointing to chemical modification of
Trp residues and/or loss of tertiary structure in general. No shift in the emission maximum
was however observed.
Mass spectrometry analysis
Undigested IFNβ1a—The data of liquid chromatography coupled to electrospray
ionization mass spectrometry (LC-ESI-MS) analysis of undigested untreated IFNβ1a (Figure
5A) are in agreement with previously reported results(31): the spectrum of the protein
represents a mixture of multiple glycoforms (mainly fucosylated and sialylated protein)
where the most abundant isoform contains one mono-fucosylated, biantennary structure
carrying two sialic acid residues, featuring a total molecular weight of 22376 Da. The
spectrum of the oxidized protein represents a single broad peak with a maximum at 22460.5
Da resulting from an overlay of multiple heterogeneously oxidized protein isoforms (Figure
5B), similar to results published for another oxidized protein (32).
Sequence-specific analysis of IFNβ1a oxidative modifications—This section
focuses on the identification of amino acid sequence-specific oxidative protein
modifications through MS/MS analysis of IFNβ1a digests and the results will be presented
in the following order: Methionine (Met), Phe, Histidine (His), Tyr and Trp oxidation. It is
noteworthy that some peptide sequences potentially contain more than one modification, and
that some MS/MS spectra may represent a mixture of peptide isoforms with the same m/z
but different locations of oxidative modifications within the sequence. Table 1 lists all the
chemically modified peptides detected. Although a few modifications were observed also in
peptides derived from the untreated protein (Table 1, last column), most modifications were
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observed in peptides from oxidized IFNβ1a and involved Met, Phe, His, Tyr and Trp
residues. Table 2 shows all the potential targets for MCO, including the ones found oxidized
in the present study. A supplementary Table S1 shows all the potential amino acid
modifications included in the settings of a database search for oxidized, reduced, alkylated
and digested IFNβ1a samples. All annotated MS/MS spectra for oxidative protein
modifications along with suggested peptide structures presented as inserts are shown in the
supplementary Figures S1–S20. Note that in the supplementary figures, the peptide
structures of the non-modified amino acid residues are displayed in a one-letter code, while
the respective full structures are drawn for the suggested oxidatively modified and alkylated/
deamidated residues.
Methionine oxidation: Met1 has been found susceptible to oxidation already by other
authors(7, 31). The b2+ ion in Figure S1, where the peptide M1SYNLLGFLQR11 is
displayed, shows the incorporation of one oxygen atom (+ 16 Da) into the sequence
Met1Ser2: here, Ser is less prone to oxidation than Met, hence the target of oxidation is
likely Met1. Figure S2 shows the same peptide with two oxygen atoms incorporated (+ 32
Da), which may represent a mixture of two sequences where either Met1 is oxidized to its
sulfone, or DOPA (formed from Tyr3) and Met sulfoxide are present together. This is
illustrated in the inserts to Figure S2, showing two potential b2+ ions, one with a mass
increase of + 16 Da (mono oxidized, indicated as Met ox) and another with the mass
increase of + 32 Da (di-oxidized, indicated as Met (ox)2). The second insert shows two
fragments with m/z 1123.57 and 1139.25, which may represent the y9+ ions for the
unmodified and oxidized form of Tyr3; the ratio of these peaks suggests that the peptide
containing oxidized Met1 and DOPA in position 3 is far less abundant than the unmodified
peptide (a fraction of less than 10%). However, this value does not necessarily reflect a
lower rate of DOPA formation compared to Met sulfone; rather, it may indicate a higher
reactivity of DOPA, resulting in DOCH and further cross-linked products. A spectrum of the
doubly charged peptide ion with m/z 678.34 in Figure S3 shows such an example where Tyr
is oxidized to DOCH based on a mass increase of 14 Da, which corresponds to the
incorporation of one oxygen atom and loss of two hydrogen atoms, albeit at very low
abundance of both y9+ and b3+−H2O sequence-indicating ions. We were also able to detect
a characteristic loss of methane sulfenic acid (CH3SOH, −64 Da, compared with the mono
oxidized sequence) from the N-terminus oxidized Met (Figure S4), which was suggested
earlier as diagnostic for identifying peptides containing oxidized Met(26, 33).
Met36 is located in a solvent exposed domain of IFNβ1a(7, 31). Figure S5a and S5b represent
the MS/MS spectra matching the sequence M36NFDIPEEIK45, in which either Met36 or
Phe38 is oxidized. These two products are not resolved by our HPLC method and the
respective spectra overlay, as evidenced by the presence of two potential fragment ions for
y8+ at m/z 990.48 and 1006.44 (Figure S5b) for oxidized Met36 and oxidized Phe38,
respectively. As additional evidence for oxidized Phe38, the ion at m/z 228.18 can be
considered, which most likely represents the b2+−H2O ion (indicated as F ox) from the
parent peptide with oxidized Phe38 (Figure S5c). Though the fraction of the peptide with
oxidized Phe38 is rather small (ca. 3–5% based on the relative abundance of fragment ion
y8+ in Figure S5b, indicated as F ox), it is noteworthy that in the control spectra (non-
oxidized IFNβ1a) both fragments at 1006.44 and at 228.18 were not observed (Figure S6a–
S6c). Altogether, these data suggest that untreated IFNβ1a already contains some oxidized
Met36 residues, whereas oxidized Phe38 is only present in oxidized IFNβ1a.
Met62 is a buried residue(7, 31). It was resistant to oxidation by hydrogen peroxide(31),
however, in conditions of MCO, we detected MS/MS spectra for the sequence
M62LQNIFAIFR71 containing the oxidized Met62 (Figure S7). Again, the spectrum for the
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loss of methane sulfenic acid in position 62, indicative of Met62 oxidation, was observed
(Figure S8).
Met117 is a solvent exposed residue(7, 31) and is most susceptible to oxidation (under mild
oxidative conditions via hydrogen peroxide), as compared to Met1, Met36 and Met62(31).
Figure S9 represents a spectrum for the sequence L116MSSLHLK123, where besides
Met117, His121 is oxidized to 2-oxo-His. The distinct b2+ and y3+ ions indicate oxidation
of Met117 and His121, respectively.
Phenylalanine oxidation: The fragment containing oxidized Phe38 (M36NF38DIPEEIK45)
has been described above in the section Methionine oxidation.
Phe50 is adjacent to several Gln residues, which may undergo deamidation, during digestion
or MCO. Figure S10 presents a typical MS/MS spectrum indicating the oxidation of Phe50,
in addition to deamidation of one of the Gln residues. Formation of pyroglutamic acid,
which should be attributed only to the cyclization of N-terminal Gln in the peptide (− 18 Da)
during the LC-MS analysis, was also detected.
Histidine and tyrosine oxidation: His oxidation to 2-oxo-His is well documented and has
been measured in proteins such as insulin(34–36). Stadtman et al. showed that His oxidation
also can yield asparagine as a potential product(37).
The sequence N86LLANVYHQINHLK99 obtained after digestion with a combination of
trypsin and endoproteinase Glu-C, contains two His residues in positions 93 and 97 and one
Tyr residue in position 92. Several observed combinations of His93 or His97 mono
oxidation (+ 16 Da on His), oxidation of both His residues (+ 32 Da), and formation of Asn
in positions 93 and 97 are shown in Figures S11, S12, S13, S14(a–b), S15(a–b), where the
respective modifications are proven by b7+, b8+, and b12+ ions, as well as y3+, y7+, y8+,
and y12++ ions. In Figure S15 are shown only the ions which differ from Figure S14.
His121 and Tyr3 oxidation was already demonstrated for the fragments L116MSSLHLK123
and M1SYNLLGFLQR11, respectively, as discussed above.
Sequence I129LHYLK134 contains two potential sites for oxidation: His131 and Tyr132. The
ions highlighted in Figure S16a fit to oxidation of either His131 or Tyr132, whereas in
Figure S16b, based on multiple fragments for the y4+ ion, oxidation of both amino acid
residues is suggested. The ions y4+−H2O and b4+ in Figure S16b, at m/z 574.26 and m/z
559.29, respectively, support the simultaneous oxidation of His and Tyr. Also, the region of
the spectrum between 200 and 400 m/z contains two peaks identified as b3+ in which His
(Figure S16b, H ox, m/z 380.28) or Tyr (Figure S16c, Y ox, m/z 364.11) are oxidized.
Furthermore, in Figure S16c is depicted the ion y3++ supporting Tyr oxidation. Altogether, it
seems that three different peptides containing either oxidized His131, oxidized Tyr132, or
both amino acids oxidized, were detected simultaneously.
In the sequence E137YSHCAWTIVR147, containing a missed cleavage site and 2 additional
oxygen atoms, there are 3 potential oxidation sites: Tyr138, His140, and Trp143. In the
spectrum shown in Figure S17 the y5+−H2O ion at m/z 656.96 rules out Trp oxidation, y8++
at m/z 501.36, in the insert, supports His oxidation, and b3+ and b4++ are in accordance with
Tyr oxidation to DOCH. Further evidence for His140 oxidation is shown in Figure S18,
where Cys is derivatized with iodoacetamide, and N-terminal Glu (E) is cleaved-off by Glu-
C.
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Tryptophan oxidation: Trp22 oxidation was detected in both the oxidized and the control
samples, suggesting a spontaneous oxidation of this residue during protein storage or
handling. Spectra presented in Figures S19 and S20 show the formation of the major
oxidative products, hydroxyl Trp (probably hydroxylated at position 5), and N-formyl
kynurenine(38, 39), respectively, as evidenced through the presence of the sequence-
indicative ions y3+−y7+ and some b+ ions, particularly b3+. In addition to Trp oxidation,
Asn25 deamidation was detected in peptide L20LWQLNGR27 from both oxidized and
control IFNβ1a, which could be expected given the highly deamidation prone N25G
sequence(40).
Cross-links—This section focuses on MS/MS identification of covalent cross-links
formed through 1,4- and/or 1,6-type addition to the electrophilic product of Tyr oxidation,
i.e. DOCH, resulting from MCO of IFNβ1a. As we have only MS/MS but no NMR data of
our reaction products, we have to assume that both reactions are possible. However, the
structures displayed in Figures 6–9 representatively show only the products of 1,4-addition.
Table 3 lists all the cross-linked peptides detected by MS/MS and Figures 6–9 represent the
corresponding MS/MS spectra along with the peptide cross-links. Data will be presented
starting from the first chemically modified electrophilic amino acid measured, i.e. DOCH in
the first observed position (Tyr3) of IFNβ1a. Data reported were obtained from IFNβ1a that
was oxidized, reduced, alkylated and digested.
Met1 – Tyr30: The free N-terminus of Met1 is a good nucleophile for 1,4- or 1,6-type
addition under our applied conditions (pH 7.2), where the N-terminal amino group is in part
deprotonated. Figure 6A, panel a, shows the MS/MS spectrum corresponding with the cross-
link between Met1 and Tyr30 in the respective tryptic peptides, as illustrated by the scheme
in Figure 6A, panel b. The series of y-ions in the peptide A (where the prefix A indicates the
ions that belong to the peptide M1SYNLLGFLQR11) of the cross-link (Ay2+ to Ay9+)
together with Ab1+ in the lower insert (zoomed region m/z 1046 –1060) demonstrate that
the peptide A is linked to peptide B through the Met1 amino group, whereas Bb1+−H2O and
Bb1+−NH3 ions (zoomed m/z region 1498–1514) indicate the involvement of Tyr30 of the
peptide B in the cross-link formation. Note that in the sequence Y30CLKDR35 both Cys and
Lysine (Lys) residues are in alkylated form (displayed by the mass of the parent peptide and
fragment ions Bb1+ and Bb5++). Furthermore, we noticed that both Met1 and Tyr3 in the
cross-linked peptide are not oxidized, suggesting that the cross-link may protect these
residues from oxidation.
Met1 – Tyr60: Figure 6B, panel a, reports the MS/MS spectrum for the cross-link involving
Met1 and Tyr60. The structure provided in panel b, where Met1 is covalently bound to
Tyr60, was drawn for the position 6 of the aromatic ring of DOPA (or DOCH), which is
sterically less hindered than the positions 1 and 2. In the peptide M1SYNLLGFLQR11, an
additional mass shift of + 16 should be attributed to Tyr3 oxidation to DOPA, as suggested
by the presence of ion Ab3++, ruling out the oxidation of another sensitive residue, Phe8.
The ion Ab2+ supports the structure shown in Figure 6B, panel b. In addition, fragments
matching ions Ay9+ and Bb3+ disprove the involvement of sequences D54AA56 and
Y3NLLGFLQR11 in the cross-link formation.
Lys105 – Phe111: Panel a of Figure 6C displays the MS/MS spectrum consistent with a
cross-link between Lys105 and Phe111. It must be noticed that the mass for this cross-link is
18 Da lower than the mass that would be expected. This is due to loss of water on Glu109 in
the sequence K108EDFTR113, which can arise from the cyclization with its N-terminal
amino group or with the more nucleophilic amino group of Lys1, which would lead to the
formation of a 1,4 diazocine-like structure as shown by Koriatopoulou et al.(41). The
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presence of an intense fragment ion Bb1++ in particular shows that the sequence
K108EDFTR113 is covalently attached to Lys105, as illustrated in Figure 6C, panel b.
Furthermore, the fragment ion By2+ proves that neither Leu106 nor Glu107 of the sequence
K105LE107 are involved in the cross-linked structure.
Lys105 – Tyr126: The cross-linked sequence R124YYGR128 with K105LE107 through
Lys105 and Tyr126 is presented in Figure 6D. Here there are two adjacent Tyr residues (in
R124YYGR128) which can be involved in the cross-link. The Ay3++ and Ay4++ related ions
however suggest that Tyr126 (and not Tyr125) serves as electron acceptor in the cross-link.
[Bb1+ Na]+ and [Bb2 + Na]+ fragments prove the involvement of Lys105 in the peptide
cross-linking. The sodiation of the respective fragment ions (except for By2+) is due to
complex formation between the C-terminal carboxyl of Arg128 and residual sodium ions
present in samples, likely due to incomplete removal of sodium phosphate buffer during
protein dialysis after MCO.
Discussion
Oxidative chemical modification of amino acid residues may alter the secondary and tertiary
protein structure, favoring interaction between protein surfaces and subsequently leading to
non-covalent aggregation. Indeed, MCO (using the oxidative system presented in this paper)
of proteins, such as growth hormone(42), IFNα2b(14), IFNβ1a(8), IgG1(16), IgG2(43), insulin
and PEGylated insulin(19), relaxin(44), recombinant SHa (29–231) prion protein(45), and
superoxide dismutase(46), have been shown to lead to extensive aggregation. Moreover,
protein aggregates generated by MCO have been shown to be particularly immunogenic. For
instance, Hermeling et al.(14, 15), using a transgenic immune tolerant mouse model,
discovered that aggregated IFNα2b, oxidized via metal catalysis was more immunogenic
than IFNα2b aggregates that were produced otherwise. More recently, van Beers and
colleagues hypothesized that a particular combination of oxidation and covalent aggregation
could be responsible for the immune response against IFNβ1a exposed to MCO, though no
particular mechanisms for chemical cross-linking were demonstrated(8). Similarly, MCO of
an IgG1 was found to produce immunogenic aggregates(16).
Here, performing an extensive mass spectrometric characterization of IFNβ1a oxidized
under conditions identical to those in the above examples (i.e., Cu2+/ascorbate catalysis), we
describe chemical modifications of multiple residues that can affect the structure of IFNβ1a.
Results of the current study, in particular, reveal that the oxidative modification of Phe and
Tyr results in an electron acceptor structure, namely DOCH, which may be involved in
IFNβ1a cross-linking through a 1,4- or 1,6-type addition mechanism of primary amines to
DOCH. The results reported in this work are in agreement with the data we recently
published using insulin as a model protein(17). However, since Met and Trp are not present
in insulin, we did not know whether these are involved in covalent cross-linking of other
proteins such as IFNβ1a. Although we detected oxidation of 4 Met residues and 1 Trp
residue in oxidized IFNβ1a, we found no evidence of Met or Trp being involved in covalent
cross-links. These data are in contrast with the common opinion that Trp oxidation could
lead to new carbonyl groups and subsequent cross-linking via Schiff base formation(47).
However, the imine structure generated through Schiff base formation is reversible unless it
is reduced with sodium borohydride or cyanoborohydride to form a secondary amine
group(48), which may explain why Trp oxidation did not seem to be involved in aggregation
of IFNβ1a.
Our data on ABS derivatization of the control samples (Figure 1B) support the hypothesis
that DOCH is an intermediate in the covalent cross-links of IFNβ1a aggregates induced by
MCO. SEC analysis under reducing conditions did not point to disulfide-mediated covalent
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cross-links. Furthermore, fluorescence spectroscopy data and MS/MS analysis helped to
exclude other potential mechanisms of aggregation, such as dityrosine formation. This
suggests that the reaction between two tyrosyl radicals is not favorable under our
experimental conditions(49).
In addition to the putative cross-links via a 1,4- or 1,6-type addition mechanism, extensive
oxidative modifications of numerous amino acid residues were induced during MCO: Met in
positions 1, 36, 62 and 117 were found to be oxidized to sulfoxides. Met1 was also oxidized
to a higher oxidation state to form Met sulfone. His oxidation to 2-oxo-His, as observed
before in insulin and other proteins exposed to similar oxidative conditions(50), targeted
IFNβ1a residues in positions 93, 97, 121, 131 and 140. Moreover, oxidative modification to
Asn was detected for His93 and His97.
Unfortunately, we failed to detect reliable spectra for ABS-derivatized peptides derived
from oxidized IFNβ1a (unpublished data). This could be attributed to either relatively low
abundance of such modifications or further chemical reactions, which may occur during the
analysis, thus interfering with the detection based on a mass increase of 179, 196 and 366
Da(27).
Table 2 demonstrates that not all of the potential targets for MCO were found oxidized.
Most of the unmodified amino acids, such as Phe70, Trp79 and Tyr125, are in fact residues
which are responsible for stabilizing the hydrophobic core of the molecule through a broad
network of hydrogen bonds(7). This could protect them from MCO and chemical cross-
linking. A similar explanation could be given for the relatively low number of detected
cross-linked peptides, which is far below the theoretically possible number of cross-links.
Besides the chemical modifications discussed above, based on far-UV CD measurements we
noticed that MCO leads to changes in IFNβ1a’s secondary structure resulting in the
conversion of alpha helices to disordered structures(29, 51). Interestingly, this was also seen
upon MCO of IFNα2b (14), but not of IgG1, which has only minor alpha helical content and
for which its betasheet content seemed to be largely maintained after MCO(16).
Nevertheless, MCO of IgG1 did result in immunogenic aggregates(16), comparable to the
observations with IFNα2b and IFNβ1a. This suggests that the change in secondary structure
in oxidized IFNα2b and IFNβ1a is not a major factor contributing to the immunogenicity of
these products. Rather, the combination of covalent aggregation and chemical modifications,
which are probably very similar across the different proteins, likely contribute to the
immunogenicity of proteins exposed to MCO. The structural changes observed in the
present study, i.e. oxidation, conformational changes and aggregation, are comparable to the
ones previously measured in IFNα2b, although at that time a detailed MS/MS analysis was
not performed and only Met oxidation was investigated(14). However, recently DOPA
formation in IFNα2b was measured by our group (unpublished data), and, considering that
both interferons share similar structural features, we suggest that the same type of chemical
modifications and cross-links could be expected in IFNα2b.
Conclusions
In this work we mapped the modifications of the primary structure in oxidized and
immunogenic aggregates of IFNβ1a, focusing on the amino acids potentially involved in
covalent cross-linking. Several oxidative modifications were identified, especially in
oxidation prone solvent-exposed amino acids. The primary role of DOPA and DOCH, i.e.
Tyr and Phe oxidation products, as electron acceptors for 1,4- or 1,6-type addition, has been
confirmed. These results are in agreement with the mechanistic studies previously
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performed on insulin, and potentially might be extended to other proteins exposed to similar
oxidative conditions.
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SEC (TSKgel Super SW2000 column) with intrinsic tryptophan fluorescence detection of
untreated IFNβ1a before (solid grey chromatogram) and after reduction and alkylation
(dashed grey) and oxidized IFNβ1a before (solid black) and after reduction and alkylation
(dashed black). The vertical dashed lines show the range of each peak: (1) mainly
representing oligomers, (2) dimers, (3) monomers, (4) fragments.
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SEC (Insulin HMWP Column) with ABS fluorescence detection of ABS-derivatized
untreated IFNβ1a (grey) and ABS-derivatized oxidized IFNβ1a (black). The vertical dashed
lines show the range of each peak: (1) mainly representing oligomers, (2) dimers and
monomers (with this column it is not possible to discriminate dimer from monomer).
Torosantucci et al. Page 16














Extrinsic fluorescence emission spectra of ABS-derivatized untreated IFNβ1a (grey), ABS-
derivatized oxidized IFNβ1a (black), and oxidized IFNβ1a (dashed black). Spectra represent
the average of two batches.
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Far-UV CD spectra of untreated IFNβ1a (grey) and oxidized IFNβ1a (black). Spectra
represent the average of two batches.
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Intrinsic steady-state fluorescence of untreated IFNβ1a (grey) and oxidized IFNβ1a (black).
Spectra represent the average of two batches.
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A: Deconvoluted mass spectrum of undigested untreated IFNβ1a and B: undigested
oxidized IFNβ1a.
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a: MS/MS spectrum for the sequence M1SYNLLGFLQR11 cross-linked through Met1 to the
sequence Y30C(IAM)LK(IAM)DR35. b: Suggested chemical structure of the cross-linked
sequence (theoretical mass 2265.11, experimental m/z 756.02, [M+H]3+, Δm from parent
peptide − 0.05).
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a: MS/MS spectrum of sequence M1SYNLLGFLQR11 cross-linked through Met1 to the
sequence D54AALTIY60E61. b: Suggested chemical structure of the cross-linked sequence
(theoretical mass 2265.11, experimental m/z 756.03, [M+H]3+, Δm from parent peptide −
0.02).
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a: MS/MS spectrum of sequence K105LE107 cross-linked through Lys105 to the sequence
K108E(−H2O)DF111TR113. b: Suggested chemical structure of the cross-linked sequence
(theoretical mass 1194.60, experimental m/z 598.30, [M+H]2+, Δm from parent peptide
+0.00).
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a: MS/MS spectrum of sodiated sequence K105LE107 linked through Lys105 to the sequence
R124YY126GR128 (the inset show the MS/MS spectrum of figure 11, panel A zoomed in the
m/z range 415–428. b: Suggested chemical structure of the cross-linked sequence
(theoretical mass 1137.56, experimental m/z 569.79, [M+H]2+, Δm from native parent
peptide + 0.02).
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Table 2
Oxidation prone amino acid residues and oxidized amino acid detected in peptides derived from oxidized
IFNβ1a.1
Methionine Phenylalanine Tyrosine Tryptophan Histidine
1 8 3 22 93*
36 15 30 79# 97*
62 38 60 143# 121*








Bold numbers: oxidized residues; bold underlined numbers: oxidized residues involved in H-bond critical for the correct folding of IFNβ1a;
underlined numbers: residues involved in H-bond critical for the correct folding of IFNβ1a (Karpusas et al.7); plain italic numbers: non-oxidized
residues.
#
Hydrophobic residues that stabilize the core of the molecule.
*
Residues that coordinate a zinc ion, responsible for dimer formation.













Torosantucci et al. Page 32
Table 3
Cross-links measured by LC-ESI-MS/MS in peptides derived from oxidized IFNβ1a after reduction,
alkylation and enzymic digestion (in blue nucleophilic amino acids, in red amino acids oxidized to DOCH).
Cross-link* Experimental m/z Charge Theoretical mass Δm
Figure 6A
756.02 3 2265.11 −0.05
Figure 6B
756.03 3 2265.11 −0.02
Figure 6C
598.3 2 1194.60 +0.00
Figure 6D
569.79 2 1137.56 +0.02
*
(IAM): alkylation with iodoacetamide; (−H2O): loss of 1 water molecule.
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